SCHEMBL2824191

SCHEMBL2824191

Cc1nc2ccc(Cl)c(Cl)c2c(OC(=O)C2CC2)c1C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.36
HTT P42858 1/20 0.36
RECQL P46063 1/20 0.36
HPGD P15428 4/20 0.35
KMT2A Q03164 4/20 0.35
NPC1 O15118 1/20 0.35
TLR9 Q9NR96 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CASP1 P29466 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GRM1 Q13255 3/20 0.34
MEN1 O00255 3/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MMP2 P08253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818881 0.88 KDM4E (0.33) MAPTHTTRECQLHPGDKMT2A
SCHEMBL2821043 0.83 ALDH1A1 (0.36) MAPTHTTHPGDKMT2ANPC1
SCHEMBL2819656 0.81 ALDH1A1 (0.36) MAPTHPGDKMT2ANPC1KDM4E
SCHEMBL2823045 0.80 KMT2A (0.33) MAPTHTTHPGDKMT2AKDM4E
SCHEMBL2825212 0.77 HPGD (0.34) HPGDKMT2ANPC1KDM4EALDH1A1
SCHEMBL2823475 0.77 USP2 (0.36) MAPTKMT2AKDM4EALDH1A1GRM1
SCHEMBL2823483 0.76 KDM4E (0.32) MAPTHPGDKMT2AKDM4EALDH1A1
SCHEMBL2821034 0.73 PTGS2 (0.33) HPGDKMT2ANPC1KDM4EMEN1
SCHEMBL1148981 0.69 SLC6A2 (0.34)
SCHEMBL2820533 0.69 L3MBTL1 (0.34) MAPTHTTHPGDKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1386914-B1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA (JP) 2010-10-27 EP disclosed
US-7022855-B2 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1559321-A1 MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS MEIJI SEIKA KAISHA LTD. (JP) 2005-08-03 EP disclosed
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2004-05-06 US disclosed
US-20040077602-A1 Mixture composition for controlling ectoparasites MEIJI SEIKA KAISHA, LTD. (JP) 2004-04-22 US disclosed
EP-1386914-A1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA LTD. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent ATL3, RABL3, RAB5C MAPT 4564/4885HTT 760/4885RECQL 369/4885
US-20040077602-A1 Mixture composition for controlling ectoparasites SF3A3, PEX3, HCN3 MAPT 4378/4885HTT 1655/4885RECQL 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.